Neurology®
The most widely read and highly cited peer-reviewed Neurology journal
Quick Search
Advanced Search
This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Golbe, L. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Golbe, L. I.
NEUROLOGY 1989;39:1109
© 1989 American Academy of Neurology

Long-term efficacy and safety of deprenyl (selegiline) in advanced Parkinson's disease

Lawrence I. Golbe

Department of Neurology, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick, NJ.

Twenty-two patients with advanced Parkinson's disease whose symptom fluctuations had initially responded to deprenyl supplementation were followed for 19 to 27 months on that drug. The improvement disappeared in most cases after a mean of 7–8 months but persists at latest follow-up in 5 patients. Transient or continuing abnormalities in liver function tests occurred in 9 patients.

Address correspondence and reprint requests to Dr. Golbe, Department of Neurology, UMDNJ-Robert Wood Johnson Medical School, CN-19, New Brunswick, NJ 08903.

Somerset Pharmaceuticals, Inc., Denville, NJ, kindly supplied deprenyl tablets and financial support for data analysis.

Presented in part at the fortieth annual meeting of the American Academy of Neurology, Cincinnati, OH, April 1988.

Received January 4, 1989. Accepted for publication in final form March 1, 1989.




This article has been cited by other articles:


Home page
 Journal of Pharmacy PracticeHome page
C. H. Waters and J. J. Chen
Pharmacologic Options for Treatment of Levodopa-Associated ``Wearing Off''
Journal of Pharmacy Practice, August 1, 2008; 21(4): 254 - 261.
[Abstract] [PDF]

Home page
 NeurologyHome page
S. Horn and M. B. Stern
The comparative effects of medical therapies for Parkinson's disease
Neurology, October 12, 2004; 63(7_suppl_2): S7 - S12.
[Full Text]

Home page
 NEJMHome page
The Parkinson Study Group
Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's Disease
N. Engl. J. Med., January 21, 1993; 328(3): 176 - 183.
[Abstract] [Full Text]

Home page
 J Geriatr Psychiatry NeurolHome page
C. H. Waters
Side Effects of Selegiline (Eldepryl)
J Geriatr Psychiatry Neurol, January 1, 1992; 5(1): 31 - 34.
[Abstract] [PDF]

Home page
 J Geriatr Psychiatry NeurolHome page
B. G. Pollock, J. M. Perel, and C. F. Reynolds
Pharmacodynamic Issues Relevant to Geriatric Psychopharmacology
J Geriatr Psychiatry Neurol, October 1, 1990; 3(4): 221 - 228.
[PDF]